<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518634</url>
  </required_header>
  <id_info>
    <org_study_id>2011-004294-87</org_study_id>
    <nct_id>NCT01518634</nct_id>
  </id_info>
  <brief_title>Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome</brief_title>
  <acronym>Stress-3</acronym>
  <official_title>Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the effect of the tricyclic antidepressant Imipramine in
      patients with longlasting health problems with no known medical explanation, defined as
      multi-organ Bodily distress syndrome (BDS). Pharmacological treatment of patients with BDS
      have never been tested, and Imipramine i low dosage (10-75 mg) has the potential of reducing
      both pain and other symptoms of bodily distress for patients with BDS. Control conditions are
      pill placebo. Study duration is 19 weeks for each of the 140 patients. End point is 13 weeks,
      i.e. after 10 weeks of 25-75 mg study drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to test the effect of Imipramine in patients with multi-organ Bodily
      distress syndrome (BDS). BDS is a unifying diagnosis that encompasses a group of closely
      related conditions such as somatization disorder, fibromyalgia, irritable bowel syndrome and
      chronic fatigue syndrome. The project consists of a double-blinded placebo controlled trial
      of treatment with the tricyclic antidepressant Imipramine in dosages of 25-75 mg. Primary
      outcome is patient-rated improvement measured by Clinical Global Improvement Scale (CGI-I).
      Secondary outcome is functional level (physical, mental and social) measured by the SF-36
      Physical Component Summary (PCS). The study requires 140 participants and study duration is
      19 weeks for each patient. End point is 13 weeks, i.e. after 10 weeks of 25-75 mg study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Clinical Improvement Scale</measure>
    <time_frame>After 13 weeks</time_frame>
    <description>Questionnaire, patient-rated improvement of health since the beginning of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>At 1 and 13 weeks</time_frame>
    <description>Questionnaire, patient-rated. Assessment of physical, social and mental functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale for pain and worst symptom</measure>
    <time_frame>At 1 and 13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Checklist (SCL)</measure>
    <time_frame>At 1, 3 and 13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Illness Checklist (FIC)</measure>
    <time_frame>At 1, 3 and 13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHODAS II</measure>
    <time_frame>At 1 and 13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Somatisation Disorder</condition>
  <condition>Somatoform Disorders</condition>
  <arm_group>
    <arm_group_label>Imipramine treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine treatment</intervention_name>
    <description>Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.</description>
    <arm_group_label>Imipramine treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. First time refered patients fulfilling diagnostic criteria for BDS multi-organ type
             with symptoms for more than 3 of 4 symptom categories

          2. Moderate or severe impact on daily life

          3. Symptoms lasting for at least 2 years

          4. Age 20-50 years

          5. Born in Denmark or have Danish parents. The patient understands, speaks, writes and
             read Danish.

        Exclusion Criteria:

          1. Presence og other physical of psychiatric condition, if the symptoms of this condition
             can not clearly be separated from symptoms of BDS

          2. Current moderate or severe depression, patients in continuous antidepressant treatment
             because of moderate or severe depression, and patients with other severe psychiatric
             disorder that demands treatment, or if the patient is suicidal.

          3. A lifetime-diagnosis of psychoses, mania or depression with psychotic symptoms
             (ICD-10: F20-29, F30-31, F32.3, F33.3)

          4. Abuse of alcohol, narcotics or drugs

          5. Pregnancy, breastfeeding or current pregnancy wish. Fertile women must use effective
             anticonception, (hormonal contraception, contraceptive injection, implant or patches,
             intrauterine system and device, vaginal ring).

          6. Treatment with all pain modulating drugs, e.g. all analgesics, antidepressants,
             antiepileptica and other types of medication with pain relieving properties must be
             discontinued at least two weeks before the treatment phase.

          7. Imipramine treatment in sufficient dosage within the last year, i.e. 25 mg daily
             continuously for at least 8 weeks.

          8. Allergy to study medication or excipients in study medication.

          9. Patients with previous med myocardial infarction, congestive heart failure, signs of
             conduction defects or abnormalities on ECG (first degree AV-block, bundle branch block
             or prolonged QT-interval), narrow-angle glaucoma, porphyria, inherited galactose
             intolerance, epilepsy, hepatic insufficiency and severe renal impairment

         10. Simultaneous use of:

               -  antipsychotics

               -  oral anticoagulants

               -  diuretics

               -  sympathomimetics and CNS-stimulating drugs (amphetamine-like drugs)

               -  all serotonergic drugs, e.g. SSRI, SNRI and TCA, the dietary supplement hypericum
                  perforatum, non-selective, irreversible or selective, reversible monoamine
                  oxidase (MAO) inhibitors, triptans, tramadol, pethidin and tryptophan

               -  the drugs cimetidine (H2-antagonist), quinidine (antiarrythmics), clonidine
                  (antihypertensive), fluconazol (antimycotics), clindamycin, clarithromycin,
                  erythromycin (antibiotics), droperidol (anaesthetic), levodopa (antiparkinson),
                  mefloquine (antimalaria), phenytoin, barbiturates, carbamazepin (antiepileptica)

               -  Bupropion (tobacco dependence), celecoxib (NSAID), cinacalcet (antiparathyroid
                  drug), duloxetine (SNRI), flufenazin (antipsychotic), fluoxetin (SSRI), gefitinib
                  (antineoplastic), moclobemid (MAO), paroxetine, Sertraline (SSRI), Terbinafine
                  (antimycotics), Yohimbin (erectile dysfunction) samt fluvoxamin (SSRI),
                  ciprofloxacin and enoxacin (microbiotic), because plasma concentration of
                  Imipramine can increase with the simultaneous use of these potent CYP2D6- and
                  CYP1A2- inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per k Fink, dr.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Clinic for Functional Disorders, Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Clinic for Functional Disorders</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Agger JL, Schr√∂der A, Gormsen LK, Jensen JS, Jensen TS, Fink PK. Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study. Lancet Psychiatry. 2017 May;4(5):378-388. doi: 10.1016/S2215-0366(17)30126-8. Epub 2017 Apr 10.</citation>
    <PMID>28408193</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bodily Distress Syndrome</keyword>
  <keyword>Medically unexplained symptoms</keyword>
  <keyword>Functional somatic symptoms</keyword>
  <keyword>Functional somatic syndromes</keyword>
  <keyword>Treatment</keyword>
  <keyword>Imipramine</keyword>
  <keyword>Tricyclic antidepressant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

